What is HC Wainwright's Forecast for Immunocore Q3 Earnings?

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Immunocore to ($0.44), improving from a previous estimate of ($0.57), and maintains a "Buy" rating with a target price of $100.00.
• Immunocore reported a quarterly earnings of ($0.20) EPS, surpassing analysts' expectations, and achieved a revenue of $130.65 million, which is a 30% increase year-over-year.
• Currently, Immunocore has an average rating of "Hold" from analysts, with a target price consensus of $58.00 amidst mixed ratings, including some "buy" and "hold" recommendations.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) - Equities research analysts at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for Immunocore in a report issued on Tuesday, August 12th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.44) for the quarter, up from their previous forecast of ($0.57). HC Wainwright currently has a "Buy" rating and a $100.00 target price on the stock. The consensus estimate for Immunocore's current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunocore's Q4 2025 earnings at ($0.88) EPS, FY2025 earnings at ($1.41) EPS, Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($1.92) EPS and FY2028 earnings at $4.47 EPS.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.01. Immunocore had a negative return on equity of 5.40% and a negative net margin of 5.70%.The firm had revenue of $130.65 million during the quarter, compared to the consensus estimate of $122.96 million. During the same period last year, the company earned ($0.23) earnings per share. The company's revenue was up 30.0% on a year-over-year basis.

Other equities research analysts also recently issued reports about the company. Wall Street Zen downgraded Immunocore from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Deutsche Bank Aktiengesellschaft initiated coverage on Immunocore in a research note on Tuesday, May 27th. They set a "buy" rating and a $65.00 price target for the company. Finally, Oppenheimer boosted their price target on Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $58.00.

Immunocore Stock Performance

NASDAQ IMCR traded up $0.76 during trading hours on Thursday, hitting $33.07. The company's stock had a trading volume of 89,421 shares, compared to its average volume of 336,071. Immunocore has a 12 month low of $23.15 and a 12 month high of $39.33. The company's 50 day simple moving average is $33.52 and its two-hundred day simple moving average is $31.23. The company has a market cap of $1.67 billion, a P/E ratio of -81.95 and a beta of 0.77. The company has a debt-to-equity ratio of 1.01, a current ratio of 5.89 and a quick ratio of 5.86.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new stake in Immunocore in the 4th quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd increased its stake in Immunocore by 4,696.3% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company's stock worth $41,000 after acquiring an additional 1,268 shares during the last quarter. Elevation Point Wealth Partners LLC bought a new stake in Immunocore in the 2nd quarter worth approximately $42,000. State of Tennessee Department of Treasury bought a new stake in Immunocore in the 2nd quarter worth approximately $132,000. Finally, Oppenheimer Asset Management Inc. bought a new stake in Immunocore in the 1st quarter worth approximately $225,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.